High HER2 expression in OS was also used to evaluate the efficacy of HER2-specific chimeric antigen receptor modified T cells (CAR T cells) in a clinical trial with 16 enrolled HER2-positive tumor in-patients with recurrent or refractory OS [175]. This evidence concerns the gene ERBB2 and neoplasm.